Medically reviewed by the CardioMender, MD Medical Team Not right now. Retatrutide is an investigational drug that the FDA has not approved for any use, so there is nothing legitimate to switch to today. Tirzepatide, by contrast, is FDA-approved and has 72-week trial data behind it. In the retatrutide vs tirzepatide debate, retatrutide’s late-stage numbers…
Medically reviewed by the CardioMender, MD Medical Team
Not right now. Retatrutide is an investigational drug that the FDA has not approved for any use, so there is nothing legitimate to switch to today. Tirzepatide, by contrast, is FDA-approved and has 72-week trial data behind it. In the retatrutide vs tirzepatide debate, retatrutide’s late-stage numbers are striking, but they come with a different tolerability profile and no head-to-head trial. If you are already using an approved medication, the useful question is not “should I switch?” but “is my current plan working, and what should I ask my clinician?” You can read how the approved options compare in our guide to tirzepatide, Mounjaro® and Zepbound®.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors targeted | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| FDA status | Approved (Zepbound for chronic weight management; Mounjaro for type 2 diabetes) | Not approved; investigational |
| Key trial | SURMOUNT-1 (Phase 3, peer-reviewed) | TRIUMPH-1 (Phase 3, sponsor topline) |
| Duration | 72 weeks | 80 weeks |
| Average weight change, top dose | −20.9% (15 mg) vs −3.1% placebo | −28.3% (12 mg) |
| Discontinuation for adverse events | 6.2% (15 mg) vs 2.6% placebo | 11.3% (12 mg) vs 4.9% placebo |
| Notable side effects | Gastrointestinal, mostly mild to moderate | Gastrointestinal, dysesthesia, heart-rate increase (Phase 2) |
| Offered at CardioMender | Yes, after medical evaluation | No |
Indirect comparison across different trials; results may vary. For real-world expectations on the approved drug, see our page on tirzepatide weight loss results.
Retatrutide is an experimental once-weekly injection described as a triple agonist (a drug that switches on three hormone receptors at once). It targets GIP, GLP-1 and glucagon receptors, according to the Phase 2 trial published in the New England Journal of Medicine (NEJM). GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are gut hormones that help regulate appetite and blood sugar. Tirzepatide activates the first two. Retatrutide adds the glucagon receptor, which is thought to influence how the body uses energy.
That third target is the reason for the interest in retatrutide. Semaglutide, by comparison, acts on the GLP-1 receptor alone; our semaglutide vs. tirzepatide comparison explains what the added GIP action means in practice. If you wonder how these medications relate to fat loss specifically, we cover it in does tirzepatide burn fat.
No. As of this writing, retatrutide is not FDA-approved for weight management or any other condition. It remains in clinical development, and Lilly has reported Phase 3 TRIUMPH results. We are not stating a regulatory submission date, because we could not verify one from a primary source.
The FDA has also been direct about unapproved products. In its published statement on unapproved GLP-1 drugs, the FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. It also notes that companies have sold unapproved drugs labeled “for research purposes” or “not for human consumption,” and it warns consumers against buying them.
By contrast, tirzepatide’s status is clear. Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who meet the label’s body mass index criteria, and Mounjaro is approved for type 2 diabetes. Cardiomender Weight Loss & Aesthetics does not currently offer retatrutide; our own retatrutide status page explains that the team would evaluate it only if it is approved. For a broader mechanism comparison, see our earlier retatrutide vs. tirzepatide overview.
The SURMOUNT-1 trial in NEJM enrolled 2,539 adults with obesity. Over 72 weeks, average weight change was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, versus −3.1% on placebo. Weight loss of at least 20% occurred in 50% of participants on 10 mg and 57% on 15 mg, compared with 3% on placebo. Discontinuation because of adverse events was 4.3%, 7.1% and 6.2% across the three doses versus 2.6% on placebo. Gastrointestinal events were the most common and were mostly mild to moderate, occurring mainly during dose escalation.
The Phase 2 retatrutide trial in NEJM included 338 adults. At 48 weeks, average weight loss was 24.2% on 12 mg, 22.8% on 8 mg and 17.1% on 4 mg, versus 2.1% on placebo. Gastrointestinal side effects were dose-related and were reduced with a lower starting dose. Heart rate rose in a dose-dependent way, peaking around week 24 and then declining.
In a May 2026 Eli Lilly announcement of TRIUMPH-1 topline results, average weight loss at 80 weeks was 28.3% on 12 mg (about 70.3 lb), 25.9% on 9 mg and 19.0% on 4 mg. Lilly reported that 45.3% of participants on 12 mg lost at least 30% of body weight. These are company-reported figures, not yet a peer-reviewed publication.
The trials differed in population, duration (72 vs. 80 weeks), dose ranges and how results were analyzed. A 28.3% figure next to a 20.9% figure does not prove one drug outperforms the other in your body. Only a head-to-head trial could do that, and none has been reported. Individual results vary widely, and no outcome is promised.
Side effects of retatrutide overlap with those of tirzepatide: nausea and other gastrointestinal effects that are dose-related and tend to appear as the dose rises. Two differences stand out in the reported data. First, dysesthesia (abnormal or uncomfortable skin sensations) was reported by 5.1%, 12.3% and 12.5% of TRIUMPH-1 participants on 4 mg, 9 mg and 12 mg, versus 0.9% on placebo. Second, discontinuation because of adverse events was 4.1%, 6.9% and 11.3% across those doses versus 4.9% on placebo. Phase 2 also showed a dose-dependent rise in heart rate.
Tirzepatide’s approved label carries a boxed warning about thyroid C-cell tumors seen in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per the Zepbound prescribing information. The human relevance of that rodent finding has not been determined. For a practical view of managing GI effects on this drug class, our guides on semaglutide side effects and how to stop nausea on semaglutide are a useful starting point. Any medication can cause side effects, and yours should be discussed with a clinician who knows your history.
Safety data for retatrutide come only from clinical trials, and long-term data do not yet exist. That is the normal state of an investigational drug. It is a much bigger concern for products sold outside the trial system, where the FDA says quality and risks are unknown. If you are weighing compounded options generally, our explainer on compounded semaglutide and tirzepatide covers what to ask.
Realistically, no. Because retatrutide is unapproved, the only legal route to it is enrollment in a clinical trial. Websites offering “research-use-only” retatrutide are the products the FDA has warned about, and CardioMender does not provide dosing, sourcing or pricing information for an unapproved drug. If a seller is marketing it to you directly, treat that as a red flag rather than a shortcut.
Use this checklist as a list of questions for your clinician, not as self-diagnosis:
Waiting is not the same as doing nothing. Protein-forward, well-planned meals support muscle and appetite control; see what to eat on tirzepatide, and read tirzepatide and muscle loss to understand why strength training matters. Our exercise for weight loss page outlines a sensible starting routine. And if you are new to treatment, how long tirzepatide takes to work sets realistic expectations. Results may vary.
Cardiomender Weight Loss & Aesthetics has been helping patients lose weight since 2009, well before the GLP-1 era; you can read more about us. Care is in person at our Pembroke Pines clinic, not telemedicine plus a prescription. Our approach pairs medication with nutrition guidance, lab work, B-vitamin injections and ongoing monitoring inside a full weight loss program, with the aim of building habits that last and, over time, tapering medication where appropriate. See what others say in our patient reviews, or learn about weight loss injections in Pembroke Pines. To be clear again: we do not offer retatrutide, and we would evaluate it only if it is approved.
Nobody can say yet. Retatrutide’s reported trial averages are higher, but the trials are different and there is no head-to-head study. It also showed more dysesthesia and higher discontinuation at the top dose. Tirzepatide is the one that is FDA-approved.
Mounjaro is a brand name of tirzepatide, approved for type 2 diabetes; Zepbound is the brand approved for chronic weight management. Retatrutide is unapproved. See Mounjaro vs. Zepbound for how the two brands differ.
Semaglutide activates only the GLP-1 receptor, while retatrutide activates three receptors. Retatrutide is still investigational, so semaglutide remains the approved option.
No. If it is approved in the future, our team would evaluate whether it fits our practice.
We cannot give a verified date. Approval depends on regulatory review of the completed trials.
No. There are no safety data on combining them, retatrutide is not approved, and you should never combine weight-loss medications without medical supervision.
Weight regain after stopping a weight-loss medication is common, which is why we recommend against pausing effective treatment to wait for a drug that is not available. Talk with your clinician before changing any plan.
Begin with a medical evaluation that reviews your history, labs and goals. Our getting started page explains what to expect.
Serving patients from Pembroke Pines and across South Florida at our Pembroke Pines, FL clinic. To talk through approved options, book your consultation at Cardiomender Weight Loss & Aesthetics or call (954) 799-6439.
Our physician-supervised weight loss and aesthetic programs are designed around your unique body, goals, and lifestyle.
